LONDON--(BUSINESS WIRE)--The cardiac rhythm management (CRM) devices market is poised to grow by USD 3.73 billion during 2020-2024, progressing at a CAGR of almost 5% during the forecast period.

The "Cardiac Monitoring & Cardiac Rhythm Management – Global Market Outlook (2019-2027)" report has been added to ResearchAndMarkets.com’s offering. The Global Cardiac Monitoring & Cardiac Rhythm ...

DUBLIN--(BUSINESS WIRE)--The "Cardiac Monitoring & Cardiac Rhythm Management Devices Market by Product and Geography - Global Forecast and Analysis 2019-2023" report has been added to ...

Boston Scientific’s (NYSE: BSX) Rhythm Management & Neuro segment accounts for around 30% of the company’s value, according to our estimates. The segment primarily includes products such as pacemakers ...

It is now apparent that the problem associated with antiarrhythmic drugs is that any beneficial effects these agents may bring about by restoring and maintaining sinus rhythm is negated by their side ...

Remote monitoring solution supports tracking of heart rate, blood pressure, and weight with real-time alerts, streamlined reviews, and timelier interventions BROOKLYN, N.Y., April 7, 2022 /PRNewswire/ ...

- New Gallant™ high voltage devices offer patients and their doctors a smartphone app and Bluetooth connectivity designed to help doctors tailor therapy to a patient's unique clinical needs - Gallant ...

New research examined a large-scale national registry of cardiac arrest cases to measure the effects of advanced airway management (AAM) on one-month outcomes after patients survived. The deep ...

Boston Scientific’s (NYSE:BSX) Cardiac Rhythm Management business accounts for roughly 20% of the company’s value, according to Trefis estimates. It includes products such as pacemakers and ...

Antiarrhythmic medications used to maintain sinus rhythm have long been the treatment of choice in atrial fibrillation. The results of five prospective randomized trials comparing the efficacy and ...